- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | 10 Stocks To Buy For Short Term: Analysts suggest buying largecap, midcap scrips for 2 weeks; Glenmark Pharma, LIC, HPCL on the list | 2 | ZEE Business | ||
| Di | Glenmark Pharma launches TEVIMBRA in India | 3 | capitalmarket.com | ||
| 18.06. | Glenmark pharma's US facility receives five observations after USFDA GMP inspection | 4 | capitalmarket.com | ||
| GLENMARK PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 17.06. | ACUCORT AB: AcuCort signs Letter of Intent (LOI) with Glenmark Pharmaceuticals for Germany and five additional European countries | 2 | Cision News | ||
| 13.06. | Glenmark's technical breakout signals rally ahead: Religare's Ajit Mishra | 4 | Times of India | ||
| 09.06. | Glenmark Pharma rises after zanubrutinib launch in India | 3 | capitalmarket.com | ||
| 02.06. | Ichnos Glenmark Innovation: Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma | 284 | PR Newswire | TRIgnite-1 study shows an overall response rate (ORR) of 74% across nine dose levels, in heavily pretreated patients with a median of six prior lines of therapy
ORR is remarkably high... ► Artikel lesen | |
| 06.05. | Ichnos Glenmark Innovation (IGI) erhält FDA-Fast-Track-Zulassung für ISB 2001 zur Behandlung des rezidivierten/refraktären multiplen Myeloms | 317 | news aktuell | New York (ots/PRNewswire) - Ergebnisse des Dosis-Eskalationsteils der klinischen Phase-1-Studie mit ISB 2001 bei Patienten mit stark vorbehandeltem multiplem Myelom werden auf der ASCO-Jahrestagung... ► Artikel lesen | |
| 05.05. | Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma | 274 | PR Newswire | Results from the dose-escalation portion of the Phase 1 clinical study of ISB 2001 in patients with heavily pretreated multiple myeloma to be presented at the 2025 ASCO Annual Meeting
NEW... ► Artikel lesen | |
| 17.04. | Glenmark Pharma's US arm set to launch generic Adderall tablets | 3 | capitalmarket.com | ||
| 16.04. | Glenmark To Launch Generic Adderall Tablets In May 2025 | 444 | AFX News | WASHINGTON (dpa-AFX) - Glenmark Pharmaceuticals Inc., USA, a wholly owned subsidiary of Glenmark Pharmaceuticals Limited (GLENMARK.NS) Wednesday announced its upcoming May 2025 launch of a generic... ► Artikel lesen | |
| 13.04. | Glenmark, Sun Pharma, Zydus Recall Medicines In US Over Manufacturing Issues | 3 | The Free Press Journal | ||
| 11.04. | Glenmark Pharmaceuticals Ltd slips for fifth straight session | 3 | capitalmarket.com | ||
| 01.04. | Glenmark Launches Vancomycin Hydrochloride For Injection In 3 Doses | 320 | AFX News | NEW DELHI (dpa-AFX) - Glenmark Pharmaceuticals Inc., USA, affiliated to India-based Glenmark Pharmaceuticals Ltd., announced Tuesday the launch of Vancomycin Hydrochloride for Injection USP... ► Artikel lesen | |
| 01.04. | Glenmark launches Vancomycin Hydrochloride for injection USP in the USA | 4 | capitalmarket.com | ||
| 25.03. | Glenmark Pharmaceuticals Ltd: Glenmark Pharmaceuticals Launches Pioneering Nutrition Program to Fight Malnutrition in the Philippines | 325 | PR Newswire | MANILA, Philippines, March 25, 2025 /PRNewswire/ -- Glenmark Pharmaceuticals Ltd. (Glenmark), a leading research-led, global pharmaceuticals company has partnered with, Health Futures Foundation... ► Artikel lesen | |
| 21.03. | Glenmark Pharma gains as arm gets USFDA nod for Olopatadine Ophthalmic solution | 3 | capitalmarket.com | ||
| 21.03. | Glenmark Gets FDA Approval For Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2% (OTC) | 439 | AFX News | NEW DELHI (dpa-AFX) - Glenmark Pharmaceuticals Inc., USA announced that it has received final approval from the U.S. Food & Drug Administration (FDA) for its Olopatadine Hydrochloride Ophthalmic... ► Artikel lesen | |
| 21.03. | Stock Alert: Hindustan Unilever, Hindalco Inds, Glenmark Pharma, Ashoka Buildcon | 5 | capitalmarket.com | ||
| 12.03. | Glenmark Pharma launches generic Empagliflozin in India | 4 | capitalmarket.com |
1 2 3 4 Weiter >>
69 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SINOPHARM | 2,057 | +0,39 % | Dividendenbekanntmachungen (16.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AEGON LTD BMG0112X1056 - 0,19 EUR ALTAGAS LTD CA0213611001 0,315 CAD 0,2007 EUR ALTEN SA FR0000071946 - 1,5 EUR ALTRIA GROUP INC US02209S1033 1... ► Artikel lesen | |
| CSPC PHARMA | 0,855 | +1,23 % | CSPC PHARMA (01093): NOMINATION COMMITTEE - TERMS OF REFERENCE | ||
| WUXI BIOLOGICS | 2,743 | +1,59 % | Aktie von WuXi Biologics büßt 3,05 Prozent ein (2,6755 €) | Am Aktienmarkt liegt der Anteilsschein von WuXi Biologics zur Stunde im Minus. Das Wertpapier kostete zuletzt 2,68 Euro. Im Wertpapierhandel hat sich heute die Aktie von WuXi Biologics zwischenzeitlich... ► Artikel lesen | |
| SHANGHAI FOSUN PHARMACEUTICAL | 1,821 | +2,77 % | Fosun Pharma prices $34.25M Nature's Sunshine share sale | ||
| DR REDDYS | 13,000 | -0,76 % | Dr. Reddy's Laboratories Ltd.: Alvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda (pembrolizumab) | Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide ("Alvotech"), and Dr. Reddy's Laboratories Ltd., (BSE:... ► Artikel lesen | |
| GEDEON RICHTER | 25,500 | +2,00 % | Gedeon Richter Plc.: Long-term Commitment to Treating Endometriosis and Improving Women's Quality of Life - Gedeon Richter at the World Congress on Endometriosis | SYDNEY, May 28, 2025 /PRNewswire/ --
Gedeon Richter had a strong presence at the World Congress of Endometriosis held this year in Sydney, Australia between 21-24 May 2025. As a Platinum... ► Artikel lesen | |
| ASPEN PHARMACARE | 5,700 | 0,00 % | ASPEN PHARMACARE HOLDINGS LIMITED - Notification in Terms of Section 122(3) of the Companies Act and Paragraph 3.83(b) of the JSE Listings Requirements | ||
| SHANGHAI PHARMACEUTICALS | 1,260 | -2,33 % | SH PHARMA (02607): FINAL DIVIDENDS FOR THE YEAR ENDED 31 DECEMBER 2024 (UPDATED) | ||
| LUYE PHARMA | 0,374 | +1,63 % | LUYE PHARMA (02186): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 28 MAY 2025 | ||
| SIHUAN PHARMACEUTICAL HOLDINGS GROUP | 0,124 | +1,64 % | SIHUAN PHARM (00460): VOLUNTARY ANNOUNCEMENT SHARE REPURCHASE | ||
| CHINA RESOURCES PHARMACEUTICAL | 0,580 | +2,65 % | Dividendenbekanntmachungen (28.05.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABO ENERGY GMBH & CO KGAA DE0005760029 - 0,65 EUR AIA GROUP LTD HK0000069689 1,3098 HKD 0,1474 EUR ALLIANZ SE ADR US0188201000 1... ► Artikel lesen | |
| CHINA SHINEWAY PHARMACEUTICAL GROUP | 0,875 | +2,34 % | Dividendenbekanntmachungen (30.04.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AG MORTGAGE INVESTMENT TRUST INC US0012285013 0,2 USD EUR ALLIED PROPERTIES REAL ESTATE INVESTMENT ... CA0194561027 0,15 CAD 0... ► Artikel lesen | |
| HANSOH PHARMACEUTICAL | 3,220 | +1,90 % | Regeneron Enters In-licensing Agreement With Hansoh Pharma For HS-20094 | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals (REGN) announced an in-licensing agreement with Hansoh Pharmaceuticals to acquire clinical development and commercial rights outside of the Chinese... ► Artikel lesen | |
| KALBE FARMA | 0,073 | +0,69 % | KLBF subsidiary partners with GE HealthCare to produce local CT scans: KLBF inaugurates new factory ... | ||
| YICHANG HEC CHANGJIANG PHARMACEUTICAL | - | - | HEC CJ PHARM (01558): JOINT ANNOUNCEMENT PROPOSED CONDITIONAL PRIVATISATION OF YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD. BY SUNSHINE LAKE PHARMA ... |
GLENMARK PHARMACEUTICALS LTD gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GLENMARK PHARMACEUTICALS LTD finden Sie auf Wallstreet Online.